Literature DB >> 18327637

Patho-biological aspects of basal-like breast cancer.

Emad A Rakha1, Maysa E El-Sayed, Jorge Reis-Filho, Ian O Ellis.   

Abstract

Breast cancer comprises a remarkably diverse group of diseases in terms of presentation, morphology, molecular profile and response to therapy. Recent gene expression profiling of breast cancer has identified specific molecular subtypes of clinical significance. Basal-like cancers (BLC) comprise a group of tumours that are characterised by an expression signature similar to that of the basal/myoepithelial cells of the breast and cluster together with BRCA1 associated tumours. Although BLC has fascinated oncologists and scientists alike due to its enigmatic clinical and pathological parameters, there is no consensus about the definition and method of identification in routine practice of this rather heterogeneous group of cancers. Furthermore, the prognostic significance of BLCs and response to specific chemotherapy regimens are still a matter debate. In this review, we discuss the molecular and morphological features, prognostic significance of BLC, and explore its impact on the concept of the breast cancer stem cell.

Entities:  

Mesh:

Year:  2008        PMID: 18327637     DOI: 10.1007/s10549-008-9952-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  31 in total

Review 1.  Wnt signaling in mammary glands: plastic cell fates and combinatorial signaling.

Authors:  Caroline M Alexander; Shruti Goel; Saja A Fakhraldeen; Soyoung Kim
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-10-01       Impact factor: 10.005

Review 2.  Signatures of breast cancer metastasis at a glance.

Authors:  George S Karagiannis; Sumanta Goswami; Joan G Jones; Maja H Oktay; John S Condeelis
Journal:  J Cell Sci       Date:  2016-04-15       Impact factor: 5.285

3.  [Overexpression of histone deacetylase 11 suppresses basal-like breast cancer cell invasion and metastasis].

Authors:  Zhang Yi; Luo Wenwen; Wang Kun; Shi Jian
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-07-30

4.  A role for the TGFbeta-Par6 polarity pathway in breast cancer progression.

Authors:  Alicia M Viloria-Petit; Laurent David; Jun Yong Jia; Tuba Erdemir; Anita L Bane; Dushanthi Pinnaduwage; Luba Roncari; Masahiro Narimatsu; Rohit Bose; Jason Moffat; John W Wong; Robert S Kerbel; Frances P O'Malley; Irene L Andrulis; Jeffrey L Wrana
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

5.  Comparative Proteome Analysis of Breast Cancer Tissues Highlights the Importance of Glycerol-3-phosphate Dehydrogenase 1 and Monoacylglycerol Lipase in Breast Cancer Metabolism.

Authors:  Kubra Karaosmanoglu Yoneten; Murat Kasap; Gurler Akpinar; Abdullah Gunes; Bora Gurel; Nihat Zafer Utkan
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069

Review 6.  Significance of rat mammary tumors for human risk assessment.

Authors:  Jose Russo
Journal:  Toxicol Pathol       Date:  2014-05-28       Impact factor: 1.902

7.  Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification.

Authors:  A Gama; A Alves; F Schmitt
Journal:  Virchows Arch       Date:  2008-08-02       Impact factor: 4.064

8.  A straightforward but not piecewise relationship between age and lymph node status in Chinese breast cancer patients.

Authors:  Ke-Da Yu; Jun-Jie Li; Gen-Hong Di; Jiong Wu; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

Review 9.  Adjuvant therapy of triple negative breast cancer.

Authors:  Edith A Perez; Alvaro Moreno-Aspitia; E Aubrey Thompson; Cathy A Andorfer
Journal:  Breast Cancer Res Treat       Date:  2010-01-22       Impact factor: 4.872

10.  May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis.

Authors:  Hai Wang; Bing Guan; Qunli Shi; Henhui Ma; Hangbo Zhou; Xuan Wang; Xiaojun Zhou
Journal:  Med Oncol       Date:  2009-12-30       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.